NewGenIvf Group Limited
NIVFNASDAQHealthcare● Active
$0.50
$-0.05(-8.49%)
Market Cap$283712
P/E Ratio—
52W High$618
52W Low$0.51
NewGenIvf Group Limited (NIVF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NIVF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 1, 2026EPS Actual
$0.51
Est. $46.35 · -98.9%
Revenue
$0.00B
Est. $0.00B · -5.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 1, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
NIVF reports quarterly as a NASDAQ-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | $2.02 | — | — | — | $0.02B | — |
| ◌ Q2 FY2026 | Jun 30, 2026 | $185.40 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | Apr 1, 2026 | $46.35 | $0.51 | -98.9% | $0.00B | $0.00B | -5.8% |
| — Q4 FY2025 | Oct 9, 2025 | — | $1.52 | — | $0.00B | — | — |
| — Q3 FY2025 | Sep 30, 2025 | — | $147.77 | — | $0.00B | — | — |
| — Q4 FY2024 | Dec 31, 2024 | — | -$0.95 | — | $0.00B | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | -$0.39 | — | $0.00B | — | — |
| — Q4 FY2023 | Dec 31, 2023 | — | -$18.82 | — | $0.00B | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
$2.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 30, 2026
EPS Actual
—
EPS Est.
$185.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 1, 2026Miss
EPS Actual
$0.51
EPS Est.
$46.35
EPS Surpr.
-98.9%
Revenue
$0.00B
Q4 FY2025
Oct 9, 2025
EPS Actual
$1.52
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Sep 30, 2025
EPS Actual
$147.77
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Dec 31, 2024
EPS Actual
-$0.95
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Sep 30, 2024
EPS Actual
-$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Dec 31, 2023
EPS Actual
-$18.82
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $2.72 | $2.72 | $2.72 | 1 |
| Q3 FY2026 | $2.02 | $2.02 | $2.02 | 1 |
| Q2 FY2026 | $185.40 | $185.40 | $185.40 | 1 |
| Q1 FY2026 | $185.40 | $185.40 | $185.40 | 1 |
| Q4 FY2025 | $15.45 | $15.45 | $15.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 1, 2026 | -98.9% | $2.26 | $2.16 | -4.42% |
| — Q4 FY2025 | Oct 9, 2025 | — | $22.80 | $22.92 | +0.53% |
| — Q3 FY2025 | Sep 30, 2025 | — | $21.72 | $21.48 | -1.10% |
| — Q4 FY2024 | Dec 31, 2024 | — | $4,980.00 | $4,860.00 | -2.41% |
| — Q3 FY2024 | Sep 30, 2024 | — | $7,488.00 | $8,148.00 | +8.81% |
| — Q4 FY2023 | Dec 31, 2023 | — | $130,800.00 | $130,800.00 | +0.00% |
| — Q3 FY2023 | Sep 30, 2023 | — | $129,360.00 | $129,840.00 | +0.37% |
| — Q2 FY2023 | Jun 30, 2023 | — | $126,600.00 | $126,600.00 | +0.00% |
Q2 FY2026-4.42%
Report Date
Apr 1, 2026
EPS Beat/Miss
-98.9%
Price Before
$2.26
Price After
$2.16
Q4 FY2025+0.53%
Report Date
Oct 9, 2025
EPS Beat/Miss
—
Price Before
$22.80
Price After
$22.92
Q3 FY2025-1.10%
Report Date
Sep 30, 2025
EPS Beat/Miss
—
Price Before
$21.72
Price After
$21.48
Q4 FY2024-2.41%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$4,980.00
Price After
$4,860.00
Q3 FY2024+8.81%
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
$7,488.00
Price After
$8,148.00
Q4 FY2023+0.00%
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
$130,800.00
Price After
$130,800.00
Q3 FY2023+0.37%
Report Date
Sep 30, 2023
EPS Beat/Miss
—
Price Before
$129,360.00
Price After
$129,840.00
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$126,600.00
Price After
$126,600.00
Avg Miss Reaction-4.42%
Beat Rate0 / 8 quarters
Largest Move+8.81% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NIVF ends December
NewGenIvf Group Limited (NIVF) most recently reported earnings on April 1, 2026 for Q2 FY2026, posting EPS of $0.51 — missing the analyst consensus of $46.35 by -98.9%. The next NIVF earnings date is expected around September 1, 2026.
Each quarter, investors track NIVF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NIVF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NIVF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NIVF earnings · 5 questionsNewGenIvf Group Limited's next earnings report is expected around September 1, 2026. NIVF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NIVF historically reports after market close (AMC).
NIVF earnings datewhen is NIVF earningsNIVF next earnings datewhen does NIVF report earningsNIVF earnings calendar
▸ Source: FMP · NewGenIvf Group Limited SEC filings · US GAAP · NewGenIvf Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026